Predictive Value of 6-Month Decline in ADAS-cog for Survival without Severe Alzheimer’s DiseaseHelmer C.a · Andrieu S.c, d · Pérès K.a · Orgogozo J.-M.a, b · Vellas B.c, d · Dartigues J.-F.a
aINSERM U593, Université de Bordeaux-2, et bFédération de Neurologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, et cINSERM U558 et dCentre Hospitalier Universitaire, Toulouse, France Dement Geriatr Cogn Disord 2007;23:168–174 (DOI:10.1159/000098516)
Background/Aims: To determine the predictive value of the 6-month evolution of the ADAS-cog score in initially mild to moderate Alzheimer’s disease (AD) patients on the risk of death or severe dementia (MMSE <10) within 2 years. Methods: Cognition was assessed every 6 months using the ADAS-cog scale in the Real.fr study, a cohort of AD patients. Six classes of ADAS-cog evolution were distinguished, from the severest deterioration (decline ≧7 points) to the greatest cognitive improvement (gain ≧4 points). Results: Among 536 AD patients, 53 (9.9%) had a 6-month decline of 7 points or more. This group with the severest deterioration was significantly associated with the risk of severe dementia or death at 2 years (relative risk, RR = 3.8, 95% confidence interval, CI = 2.1–6.8), even after adjustment for baseline MMSE, disability and ADAS-cog score (RR = 2.6, 95% CI = 1.4–5.0). In addition, subjects with a decline by at least 4 points were also at greater risk of severe dementia. Conclusion: These results confirm the value of the ADAS-cog scale as a judgement criterion in clinical trials since it is a good surrogate marker of long-term prognosis. The proportion of fast decliners on the ADAS-cog could be a helpful judgement criterion for future trials in AD.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50